Invex Therapeutics
ASX:IXCMelbourne, Australia· Est.
Repurposing Exenatide to treat raised intracranial pressure in neurology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Repurposing Exenatide to treat raised intracranial pressure in neurology.
NeurologyNeuroscience
Technology Platform
Repurposing of the approved GLP‑1 receptor agonist Exenatide (Presendin™) to lower intracranial pressure via modulation of cerebrospinal fluid dynamics and cerebral blood flow.
Opportunities
Successful IIH trial data could enable rapid market entry and open pathways to larger neurological markets such as stroke and TBI, leveraging the same GLP‑1 platform.
Risk Factors
Reliance on a single repurposed molecule, regulatory uncertainty for a new indication, and limited financial runway without additional capital raises.
Competitive Landscape
Competing GLP‑1 candidates (e.g., semaglutide) are being explored for IIH, but Presendin™ benefits from an established safety profile and early clinical data, offering a differentiation advantage.